

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

Pacific Blue(TM) anti-mouse CD3

RRID:AB_493644

Type: Antibody

Proper Citation

BioLegend Cat# 100213, RRID:AB_493644

Antibody Information

URL: http://antibodyregistry.org/AB_493644

Proper Citation: BioLegend Cat# 100213, RRID:AB_493644

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_493644

Vendor: BioLegend

Catalog Number: 100213

Alternative Catalog Numbers: 100214

Record Creation Time: 20250820T024654+0000

Record Last Update: 20250820T143013+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-mouse CD3.

No alerts have been found for Pacific Blue(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Saraiva GN, et al. (2025) CD38 is a key mediator of NAD⁺ depletion in the brain of ZIKV-infected mice. *iScience*, 28(12), 114018.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

Golomb SM, et al. (2025) Temporal dynamics of immune cell transcriptomics in brain metastasis progression influenced by gut microbiome dysbiosis. *Cell reports*, 44(3), 115356.

Frey HC, et al. (2025) A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum. *iScience*, 28(3), 112043.

Wang X, et al. (2025) Machine-learning-assisted universal protein activation in living mice. *Cell*, 188(14), 3696.

Shi W, et al. (2024) Lactic acid induces transcriptional repression of macrophage inflammatory response via histone acetylation. *Cell reports*, 43(2), 113746.

Cong J, et al. (2024) Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8⁺ T cell effector functions. *Immunity*.

Bülow S, et al. (2024) Bactericidal/permeability-increasing protein instructs dendritic cells to elicit Th22 cell response. *Cell reports*, 43(3), 113929.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8⁺ T cells. *Cell*, 187(9), 2288.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. *Cell reports. Medicine*, 5(2), 101397.

Mortales C, et al. (2023) NL-201 Upregulates MHC-I Expression and Intratumoral T-cell Receptor Diversity, and Demonstrates Robust Antitumor Activity as Monotherapy and in Combination with PD-1 Blockade. *Cancer immunology research*, 11(7), 1000.

Yang JF, et al. (2023) Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8+ T cell metabolic fitness and function in tumors. *Science immunology*, 8(87), eabq2424.

Briukhovetska D, et al. (2023) T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. *Immunity*, 56(1), 143.

Domenjo-Vila E, et al. (2023) XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections. *Cell reports*, 42(2), 112123.

Gawish R, et al. (2022) ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFN γ -driven immunopathology. *eLife*, 11.

Frost JN, et al. (2021) Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. *Med (New York, N.Y.)*, 2(2), 164.